Core-009

自成立以来，转化病理学核心一直由Sue Ellen Martin博士领导。 成立于1998年。这个由NCI资助的共享资源为癌症中心提供了一个访问点 需要组织采购和银行服务的成员。核心的具体目标是：1）采购， 库、处理、跟踪和分发新鲜/冷冻和福尔马林固定、石蜡包埋（FFPE）正常 实验室、流行病学和医院临床所需的肿瘤组织生物标本 研究正在进行的南加州大学诺里斯癌症中心成员; 2）采购，维护和跟踪丢弃 通过癌症监测计划确定的来自当地区域医院的FFPE肿瘤组织块 (CSP)对于基于人群的LA残留组织储存库（RTR），其直接对应于 集水区; 3）确保所有使用组织的研究都有适当的IRB批准文件， 除非有签署的书面知情同意书，否则不得发布受保护的健康信息（PHI）;以及4） 结合组织采购和库存方法创新，以满足制药商领导的研究。的 核心仍然有三个组成部分，或武器：成人，儿科和人口为基础。所有这些 Arms提供综合的一站式服务。 在项目期间取得的成就包括：1）癌症中心成员使用同行评审 赠款。在最近的报告年度（2013-2014财年），91名癌症中心成员使用了核心， 其中53个（58%）获得了同行评审资金。这比上一个项目期增加了140%; 2） 更高的退款。使用费占总预算的27%，高于项目期间的17%; 3)增加新鲜/冷冻和FFPE组织的收集和分布。这有助于 癌症中心成员在理解参与的机制方面取得了重大研究进展， 致癌作用，特别是在胃癌、结肠直肠癌、尿路上皮癌和肺癌、神经母细胞瘤和霍奇金淋巴瘤中， 淋巴瘤

The Translational Pathology Core has been continuously under the leadership of Dr. Sue Ellen Martin since its founding in 1998. This NCI-funded Shared Resource provides a single point of access for Cancer Center members needing tissue procurement and banking services. The specific aims of the Core are to: 1) procure, bank, process, track, and distribute both fresh/frozen and formalin-fixed, paraffin embedded (FFPE) normal and tumor tissue biospecimens necessary for laboratory-based, epidemiological, and hospital-based clinical studies being conducted by USC Norris Cancer Center members; 2) procure, maintain, and track discarded FFPE tumor tissue blocks from local regional hospitals identified through the Cancer Surveillance Program (CSP) for the population-based LA Residual Tissue Repository (RTR), which corresponds directly to the catchment area; 3) ensure that all studies utilizing tissue have appropriate documented IRB approval and that protected health information (PHI) is not released unless there is a signed written Informed Consent; and 4) incorporate innovations in tissue procurement and banking methodology to meet investigator-led research. The Core continues to have three components, or Arms: Adult, Pediatric and Population-Based. Together, these Arms provide an integrated, single stop service. Accomplishments during the project period include: 1) increased usage by Cancer Center members with peerreviewed grants. In the most recent reporting year (FY 2013-2014), 91 Cancer Center members used the Core, of which 53 (58%) had peer-reviewed funding. This is an increase of 140%, from the prior project period; 2) higher chargebacks. User fees account for 27% of the total budget, up from 17% over the project period; and 3) increased collection and distribution of both fresh/frozen and FFPE tissues. This has contributed to significant research advances by Cancer Center members in understanding of the mechanisms involved in carcinogenesis, particularly in gastric, colorectal, urothelial and lung cancers, neuroblastoma and Hodgkin’s lymphoma.